Xenon files its seizure-drug application while pausing new psychiatry enrollment
Xenon ($XENE) submitted a US new-drug application for azetukalner to treat focal seizures, supported by its X-TOLE and X-TOLE2 studies and more than 1,500 patient-years of exposure. Submission is an application milestone, not confirmation that the FDA has accepted the filing or approved the medicine. Separately, Xenon voluntarily paused new enrollment in its depression and bipolar programs after neuropsychiatric adverse events. Patients already enrolled can continue, and the epilepsy studies are
0